About
Christopher Barbieri is an Associate Professor at the Weill Cornell Medicine Graduate School of Medical Sciences, affiliated with the Department of Cell & Developmental Biology. His research is centered on the molecular underpinnings of prostate cancer and other urologic diseases, with a strong emphasis on genomic and transcriptomic analysis to identify novel alterations in human cancers.
His research interests span Cancer Biology, Genomics, Transcriptomics, and Cell Signaling. He employs cutting-edge technologies including genetically engineered mouse models and organotypic culture systems to functionally model molecular subtypes of prostate cancer. The long-term goal of his lab is to define distinct molecular classes of prostate cancer, understand their drivers and signaling pathways, and identify therapeutic vulnerabilities for translation into clinical care.
The trends in his research, though specific publications are not listed, emphasize integrative omics approaches, functional validation in advanced preclinical models, and translational relevance to patient care. His work contributes significantly to the molecular stratification of prostate cancer and the development of targeted therapies.
- Affiliated with the Tri-Institutional PhD Programs
- Member of the Cancer Biology research focus area
- Faculty in the BCMB Allied Program (Biochemistry, Cell & Molecular Biology)
Dr. Barbieri advises graduate students through the PhD programs at Weill Cornell and is involved in training the next generation of biomedical scientists. While specific grants are not mentioned, his research program likely involves funding from major federal and private agencies supporting cancer genomics and translational research. He is actively engaged in the academic and research mission of the Graduate School of Medical Sciences.
He leads the Barbieri Lab, which focuses on functional modeling of prostate cancer subtypes using state-of-the-art in vivo and in vitro systems. The lab integrates genomics with experimental validation to bridge discovery and therapy.
